Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Guangzhou Link Health in $85 Million Deal for Cancer Drug from 4SC

publication date: May 31, 2016
Guangzhou LingSheng Pharma Tech (Link Health) in-licensed greater China rights to a cancer drug from Germany's 4SC AG (FSE: VSC) in a deal worth up to $84.7 million in upfront and milestone payments. The drug, 4SC-205, inhibits Eg5, the kinesin spindle protein, which plays a key role in cell division. 4SC says 4SC-205 does not have the serious side effects of other Eg5 inhibitors. Link Health will be responsible for China clinical development and commercialization of 4SC-205, which has completed a Phase I trial. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital